1999 Fiscal Year Final Research Report Summary
Detection of tumor-rejection antigens of lung cancer and development of lung cancer vaccines.
| Project/Area Number |
09671401
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
HAYASHI Akihiko Kurume Univ., Sch., Med., Dep. Surg., Lecturer, 医学部, 講師 (70180958)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITOH Kyogo Kurume Univ., Sch. Med., Dep. Immunol, Professor, 医学部, 教授 (50125499)
GOMI Shinnya Kurume Univ., Sch., Med., Dep. Immunol., Res. Associa, 医学部, 助手 (30289368)
|
|---|
| Project Period (FY) |
1997 – 1999
|
| Keywords | Lung cancer / Tumor-rejection / Gene / Cancer Vaccine / HLA-class I / Peptide antigen / Specific immunotherapy / HLA-A24 |
|---|
| Research Abstract |
A main objective of this research project is to identity tumor rejection antigens of lung cancers that were recognized by HLA-class I-restricted cytotoxic T lymphocytes (CTLs). We have identified four tumor-rejection antigens (SART3, cyclophilin B, ART1 and ART4) that were recognized by HLA-A24-restricted CTLs. The three (SART-3, ART-1 and ART-4) tumor rejective antigens were newly identified molecules, while the remaining one (cyclophilin B) was a known molecule. These tumor rejection antigens were broadly expressed in the majority of lung cancers. Peptide antigens recognized by these CTLs, and those capable of inducing HLA-class I restricted CTLs from peripheral blood mononuclear cells (PBMCs) of lung cancer patients were also identified in these tumor-rejection antigens. Some of these peptides (Cyclophilin BィイD284-92ィエD2, Cyclophilin BィイD291-99ィエD2) are currently used for phase I clinical studies as cancer vaccines in HLA-A24ィイD1+ィエD1 lung cancer patients in our Kurume University Hospital. These basic and clinical research shall provide new insight for better understanding of molecular basis of T cell-mediated recognition of cancer cells. Further, these studies may open the door of specific immunotherapy of lung cancers.
|
-
-
-
-
-
-
-
[Publications] Shichijo, S., Hooshino, H., Koufuji, K., Hayashi A., Kawamoto, M., Kikuchi, M.,: "Detection of MAGE-4 protein in sera of lung cancer patients."JJCR. 88. 414-419 (1997)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Gomi, S., Nakao, M., Niiya, F., Imamura,Y., Kawano, K., Nishizaka, S., Hayashi A, Sobao, Y., Oizumi, K., and Itoh, K.: "A cyclophilin B gene encodes antigenic peptides recognized by HLA-A24-restricted and tumor-specific CTLs."J. Immunol. 163. 4994-5004 (1997)
Description
「研究成果報告書概要(欧文)」より
-
-
[Publications] Yang, D., Nakao, M., Shichijo, S., Sasatomi, T., Takasu, H., Matsumoto, H., Mori, K., Hayashi A., Yamana, H., Shirouzu, K., and Itoh, K.: "Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients."Cancer Research. 59. 4056-4063 (1999)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Shichijo, S., Nakao, M., lmai, Y., Takasu, H., Hayashi A, Yamana, H., and Itoh, K.: "Japan Scientific Societies Press, Tokyo"A gene encoding squamous cell carcinoma antigens recognized by cytotoxic T lymphocytes.In: Reccnt Advances of Human Tumor Immunology and Immunotherapy.(Gann Monograph on Cancer Research No. 48). (eds) Kikuchi, K., and Sato, T.,. 43-51 (1999)
Description
「研究成果報告書概要(欧文)」より
-
[Publications] Itoh, K., Shichijo, S., lnoue, Y., Hayashi A, Toh, U., Yamana, H.: "Springer-Verlag Tokyo (in press.)"SART1 gene encoding squamous cell carcinoma antigen recognized by cytotoxic T lymphocytes. In: Cell Therapy. (eds). Ikeda, Y., and Kawakami, Y.,. (2000)
Description
「研究成果報告書概要(欧文)」より
